ATE188740T1 - Viruspartikel mit veraendertem wirtspektrum - Google Patents

Viruspartikel mit veraendertem wirtspektrum

Info

Publication number
ATE188740T1
ATE188740T1 AT91915104T AT91915104T ATE188740T1 AT E188740 T1 ATE188740 T1 AT E188740T1 AT 91915104 T AT91915104 T AT 91915104T AT 91915104 T AT91915104 T AT 91915104T AT E188740 T1 ATE188740 T1 AT E188740T1
Authority
AT
Austria
Prior art keywords
methods
altered host
incorporation
virus particles
disclosed
Prior art date
Application number
AT91915104T
Other languages
English (en)
Inventor
Jiing-Kuan Yee
Nobuhiko Emi
Theodore Friedman
Douglas J Jolly
Original Assignee
Univ California
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24642035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE188740(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California, Chiron Corp filed Critical Univ California
Application granted granted Critical
Publication of ATE188740T1 publication Critical patent/ATE188740T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation
    • C12N2740/13062—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT91915104T 1991-02-19 1991-08-09 Viruspartikel mit veraendertem wirtspektrum ATE188740T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65863291A 1991-02-19 1991-02-19
PCT/US1991/005699 WO1992014829A1 (en) 1991-02-19 1991-08-09 Viral particles having altered host range

Publications (1)

Publication Number Publication Date
ATE188740T1 true ATE188740T1 (de) 2000-01-15

Family

ID=24642035

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91915104T ATE188740T1 (de) 1991-02-19 1991-08-09 Viruspartikel mit veraendertem wirtspektrum

Country Status (6)

Country Link
EP (1) EP0572401B2 (de)
JP (1) JP3547129B2 (de)
AT (1) ATE188740T1 (de)
CA (1) CA2104396C (de)
DE (1) DE69131908T3 (de)
WO (1) WO1992014829A1 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512421A (en) * 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
WO1993020221A1 (en) * 1992-04-03 1993-10-14 Young Alexander T Gene therapy using targeted viral vectors
AU689755B2 (en) * 1992-09-22 1998-04-09 Biofocus Discovery Limited Recombinant viruses displaying a nonviral polypeptide on their external surface
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
ATE263252T1 (de) * 1992-11-09 2004-04-15 Us Health Erzielbare vektorenpartikel
JPH09503656A (ja) * 1993-09-03 1997-04-15 チロン ビアジーン インコーポレイティド 移植片拒絶の抑制方法
AU3635695A (en) * 1994-09-19 1996-04-09 Board Of Trustees Of The Leland Stanford Junior University Methods for genetically modifying hematopoietic stem cells
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
US5681746A (en) * 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
US6117681A (en) * 1995-03-29 2000-09-12 Bavarian Nordic Research Inst. A/S Pseudotyped retroviral particles
US5750396A (en) * 1995-05-08 1998-05-12 St. Judes Children's Research Hospital Stable virus packaging cell lines
AU7470096A (en) * 1995-10-05 1997-04-28 Chiron Corporation Retroviral vectors pseudotyped with srv-3 envelope glycoprotein sequences
US5910434A (en) * 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
US6723531B2 (en) 1996-04-05 2004-04-20 The Salk Institute For Biological Studies Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
US5928638A (en) * 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
US6133027A (en) * 1996-08-07 2000-10-17 City Of Hope Inducible expression system
US5739018A (en) * 1996-08-07 1998-04-14 The Regents Of The University Of California Packaging cell lines for pseudotyped retroviral vectors
US6183993B1 (en) 1996-09-11 2001-02-06 The General Hospital Corporation Complement-resistant non-mammalian DNA viruses and uses thereof
WO1998012311A2 (en) 1996-09-11 1998-03-26 The General Hospital Corporation Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell
BR9712978A (pt) 1996-09-11 2000-04-18 Gen Hospital Corp Vìrus de dna de não-mamìferos possuindo uma proteìna de revestimento alterada
US6818209B1 (en) 1998-05-22 2004-11-16 Oxford Biomedica (Uk) Limited Retroviral delivery system
US6300488B1 (en) 1997-07-10 2001-10-09 The Salk Institute For Biological Studies Modified lepidopteran receptors and hybrid multifunctional proteins for use in transcription and regulation of transgene expression
US7078483B2 (en) 1998-04-29 2006-07-18 University Of Southern California Retroviral vectors including modified envelope escort proteins
US6333318B1 (en) 1998-05-14 2001-12-25 The Salk Institute For Biological Studies Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
ATE435297T1 (de) * 1998-05-22 2009-07-15 Oxford Biomedica Ltd Retrovirales verabreichungssystem
AU5122499A (en) 1998-07-27 2000-02-21 Genentech Inc. Improved transformation efficiency in phage display through modification of a coat protein
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
GB9907414D0 (en) 1999-03-31 1999-05-26 Cancer Res Campaign Tech Improvements relating to prodrugs
US7504253B2 (en) 1999-06-11 2009-03-17 The Burnham Institute For Medical Research Nucleic acid encoding proteins involved in protein degradation, products and methods related thereof
US7057015B1 (en) 1999-10-20 2006-06-06 The Salk Institute For Biological Studies Hormone receptor functional dimers and methods of their use
US6864085B2 (en) 1999-12-14 2005-03-08 Novartis Ag Bovine immunodeficiency virus (BIV) based vectors
US7335646B2 (en) 2000-03-13 2008-02-26 Engene, Inc. Compositions and methods for regulated protein expression in gut
US6656718B2 (en) 2000-07-07 2003-12-02 Cancer Research Technology Limited Modified carboxypeptidase enzymes and their use
EP1373536B9 (de) 2001-03-13 2009-09-02 Novartis AG Lentivirale verpackungskonstrukte
CA2524619A1 (en) 2005-11-22 2007-05-22 Ottawa Health Research Institute Novel stem cells, nucleotide sequences and proteins therefrom
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
CA2683287A1 (en) 2006-11-27 2008-12-18 Patrys Limited Novel glycosylated peptide target in neoplastic cells
CA2677273A1 (en) 2007-02-06 2008-08-14 Tai-June Yoo Use of a composition comprising a cytokine encoding nucleic acid for treating alzheimer's disease
EP2537522A1 (de) 2007-08-02 2012-12-26 California Stem Cell, Inc. Neuronale Vorläuferzellen und Verfahren zur Ableitung und Reinigung neuronaler Vorläuferzellen aus embryonischen Stammzellen
EP2215231A4 (de) 2007-10-15 2010-12-01 Univ Queensland Expressionssystem zur modulation einer immunantwort
AU2008323853B8 (en) 2007-11-08 2014-07-24 Beth Israel Deaconess Medical Center Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-CD3/CD28
US8877896B2 (en) 2008-02-15 2014-11-04 Tufts University Compositions, methods and kits for modeling, diagnosing, and treating complement disorders
AU2009215118B2 (en) 2008-02-15 2015-01-22 Tufts University A humanized model of membrane attack complex (MAC) formation on murine retina and compositions, kits and methods for treatment of macular degeneration
DK3192874T3 (da) 2008-06-18 2019-12-16 Oxford Biomedica Ltd Virusoprensning
US8999919B2 (en) 2008-10-22 2015-04-07 Trustees Of Dartmouth College Compositions and methods for inhibiting the interaction between CFTR and CAL
US8211487B2 (en) 2008-11-26 2012-07-03 Srinivasan Damodaran Inhibition of ice crystal growth
WO2010117057A1 (ja) 2009-04-10 2010-10-14 協和発酵キリン株式会社 抗tim-3抗体を用いた血液腫瘍治療法
PT2426148E (pt) 2009-04-27 2015-10-26 Kyowa Hakko Kirin Co Ltd Anticorpo anti-rá-il-3 para se utilizar no tratamento de tumores do sangue
WO2011060233A1 (en) 2009-11-11 2011-05-19 The Trustees Of The University Of Pennsylvania Anti-tem1 antibodies and uses thereof
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
CA2843684A1 (en) 2010-08-13 2012-02-16 Tufts University Compositions, kits and methods for treatment of macular degeneration using soluble membrane-independent cd59 protein
WO2013040517A2 (en) 2011-09-15 2013-03-21 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center IMMUNOTHERAPY AND DIAGNOSIS OF MUCORMYCOSIS USING CotH
US9783610B2 (en) 2012-04-27 2017-10-10 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
EP2953970A4 (de) 2013-02-08 2016-06-29 Misfolding Diagnostics Inc Transthyretinantikörper und verwendungen davon
EP3003393A4 (de) 2013-06-04 2017-01-11 The Johns Hopkins University Dreiteilige theranostische krebs-nukleinsäurekonstrukte
WO2014197599A1 (en) 2013-06-04 2014-12-11 The Johns Hopkins University Peg-prom mediated surface expression of avidin/streptavidin
EP3004153B1 (de) 2013-06-04 2019-10-30 Virginia Commonwealth University Rekombinantes cytokin für eine krebstherapie
WO2014197586A1 (en) 2013-06-04 2014-12-11 Virginia Commonwealth University Mda-9/syntenin promoter to image and treat metastatic cancer cells
EP3003022B1 (de) 2013-06-04 2017-11-22 Virginia Commonwealth University Verwendung eines trunkierten ccn1-promotors für krebsdiagnostik, therapeutika und theranostika
US20160152952A1 (en) 2013-06-25 2016-06-02 Temple University-Of The Commonwealth System Of Higher Education Cortical Bone-Derived Stem Cells
ES2872537T3 (es) 2014-08-28 2021-11-02 Univ Tufts Composiciones, métodos y kits para el tratamiento de trastornos relacionados con el complemento
US9901639B2 (en) 2015-02-13 2018-02-27 Temple University—Of the Commonwealth System of Higher Education Bone marrow origin progenitor cell or endothelial progenitor cell in combination with DNMT1 gene therapy for vascular repair in metabolic disease
CN105372433A (zh) * 2015-08-21 2016-03-02 深圳出入境检验检疫局动植物检验检疫技术中心 一种水泡性口炎病毒抗体快速检测试纸条
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
KR102895580B1 (ko) 2015-12-09 2025-12-03 진강 메디신 (오스트레일리아) 피티와이 엘티디 치료를 위한 면역조절용 조성물
AU2017250191A1 (en) 2016-04-13 2018-11-08 Orimabs Ltd. Anti-PSMA antibodies and use thereof
EP3299460A1 (de) 2016-09-26 2018-03-28 Johann Wolfgang Goethe-Universität Frankfurt am Main Neuartige verbindungen und verfahren zur modulation der ubiquitinierung
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
JP2020531514A (ja) 2017-08-22 2020-11-05 モナシュ・ユニヴァーシティ 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節
CA3090997A1 (en) 2018-02-12 2019-08-15 Trustees Of Tufts College Cd59 for inhibiting inflammasome activation
US12233135B2 (en) 2018-04-11 2025-02-25 Precision Molecular Inc. Therapeutic constructs for treating cancer
US12098212B2 (en) 2019-08-12 2024-09-24 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
EP4413038A1 (de) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Pd-l1-bindende affimere
EP4412711A1 (de) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Serumhalbwertszeiterweiterte pd-l1-bindende polypeptide
CN118369333A (zh) 2021-11-19 2024-07-19 詹森生物科技公司 用表达可溶性cd59的基因疗法载体治疗地图样萎缩的方法
EP4514389A1 (de) 2022-04-29 2025-03-05 Purinomia Biotech, Inc. Verfahren und zusammensetzungen zur behandlung von eosinophil-bedingten erkrankungen und störungen
WO2025074268A1 (en) 2023-10-02 2025-04-10 Janssen Biotech, Inc. Methods for treating macular degeneration

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1310924C (en) * 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
FR2619012B1 (fr) * 1987-08-07 1989-12-22 Pasteur Institut Vaccins dont l'epitope caracteristique est incorpore dans une proteine de picornavirus, notamment de poliovirus
WO1990005538A1 (en) * 1988-11-14 1990-05-31 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Parvovirus capsids
JPH04504361A (ja) * 1989-04-05 1992-08-06 ノバセル　コーポレイション 感染性標的化複製―欠陥ビリオン
AU5848390A (en) * 1989-06-01 1991-01-07 Applied Biotechnology, Inc. Self-assembled, defective, non-self-propagating viral particles
AU5642690A (en) * 1989-08-21 1991-04-03 Hans-Peter Brackmann Portable device for the acquisition of data concerning therapy-relevant events
WO1991006658A2 (en) * 1989-10-24 1991-05-16 Cetus Corporation Infective protein delivery system

Also Published As

Publication number Publication date
DE69131908T3 (de) 2008-04-03
CA2104396A1 (en) 1992-08-20
JPH06504905A (ja) 1994-06-09
EP0572401A1 (de) 1993-12-08
EP0572401B1 (de) 2000-01-12
AU663470B2 (en) 1995-10-12
DE69131908T2 (de) 2000-08-17
CA2104396C (en) 2000-10-10
WO1992014829A1 (en) 1992-09-03
DE69131908D1 (de) 2000-02-17
JP3547129B2 (ja) 2004-07-28
AU8430291A (en) 1992-09-15
EP0572401B2 (de) 2007-11-07

Similar Documents

Publication Publication Date Title
ATE188740T1 (de) Viruspartikel mit veraendertem wirtspektrum
NO871785D0 (no) Fremgangsmaate for fremstilling av et proteinprodukt, samt vektorsystem for fremgangsmaatens utfoerelse.
IL89701A0 (en) Recombinant retroviruses,method for the production thereof and pharmaceutical composition containing the same
CA2066053A1 (en) Recombinant retroviruses delivering vector constructs to target cells
DE69636878D1 (de) Zirkuläres DNA Molekül mit einem abhängigen Replikationsursprung, seine Herstellungsverfahren und seine Verwendung in der Gentherapie
DK0561890T3 (da) DNA ekspressionssystemer baseret på alphavira
DE3852221D1 (de) Tierische Zelle mit darin eingeführtem antigenem Protein.
ATE316571T1 (de) Purifikation von viruspräparaten
DK79887A (da) Vektor til ekspression af gamma-interferon i pattedyrceller, fremgangsmaade til fremstilling deraf, det vundne produkt samt farmaceutisk praeparat indeholdende gamma-interferonet
DE69921435D1 (de) Verfahren zur Inaktivierung vom umhüllten Viren in einem Viruspräparat mit Adenoviren
DE69535704D1 (de) EXPRESSIONSPLASMIDE, DURCH EINEN osmB PROMOTER REGULIERT
ATE101200T1 (de) Impfstoffe gegen menschliche respiratorische viren.
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
EP0676413A3 (de) Interferon alpha/beta bindendes Protein, seine Herstellung und Anwendung.
NO178870C (no) Fremgangsmåte for fremstilling av modifisert Eglin B eller C samt DNA, ekspresjonsvektor og vertsmikroorganisme
EP0836484A4 (de) In-vitro verpackung von adeno-assozierten virus dns
Will et al. Hepatitis B after infection of a chimpanzee with cloned HBV DNA
JPS5545618A (en) Thermal treatment of fraction containing glycoprotein which accelerates differentiation and proliferation of human granulocyte
ES2175184T3 (es) Virus que expresan proteinas toxicas y leneas celulares productoras.
Bosworth et al. Evaluation of age-related effects on the antiviral activity of interferon and induction of 2-5A synthetase in testicular cell cultures derived from swine of various ages
EP0460217A4 (en) Cdna of orsv gene
ITRM930551A0 (it) Procedimento per la propagazione del virus dell'epatite c in colture cellulari animali non linfoblastoidi e relativo prodotto.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties